Telix

Telix Opens Licensing, Co-Development and M&A Talks in Five Areas

Global – October 21, 2026 -- Telix is soliciting partners across five areas of radiopharmaceutical development, with deal structures ranging from licensing and co-development to strategic M&A.

Telix targets therapeutic assets with established proof of concept

In therapeutics, Telix is looking for theranostic oncology programs in urologic and neurologic cancers, other solid tumors and hematologic malignancies. Candidates must have established proof of concept. Telix says they should benefit from its fully integrated radiopharmaceutical platform and strengthen its pipeline, platform and long-term growth.

Telix Schedules New York R&D Day and Melbourne Capital Markets Day

Telix Schedules New York R&D Day and Melbourne Capital Markets Day

Melbourne – October 21, 2026 -- Telix will hold an in-person Research and Development Day in New York City on September 22, 2026, followed by a Capital Markets Day in Melbourne on November 4, 2026, giving institutional investors two scheduled windows into its strategy and pipeline.

Telix opens its New York R&D Day to institutional investors and analysts on September 22

The session runs from 8:30 a.m. to 12:30 p.m. EDT and will cover the company's therapeutic and precision medicine pipeline, along with scientific, clinical and strategic developments across the portfolio. Attendance is in person only and requires advance registration. Venue, agenda and presentation materials will go to registered attendees.